Conclusion. Hence, PEG-Hi is considered safe in patients Pharmacodynamics and pharmacokinetics of polyethylene glycolwith CRF, but dosing and/or dose intervals should be adjusted hirudin in patients with chronic renal failure.
tendency, osteoporosis, alopecia, and, increasingly, hep- of hirudin has proved to be an effective anticoagulant decreased as follows: C TB from 23.3 Ϯ 6.6 (IB) to 2.9 Ϯ 0.6 mL/min (IV), C Renal from 7.8 Ϯ 5.0 (IB) to 0.8 Ϯ 0.5 mL/min and antithrombotic agent, allowing a new approach to (IV) , and FE o-t from 40.2 Ϯ 18.9% (IB) to 12.6 Ϯ 13.0% (IV).
the prevention and treatment of thromboembolic dis- regular hemodialysis treatment [18, 19] . To achieve a prolongation of the elimination half-life, Lyophilized PEG-Hi was reconstituted with is well tolerated by healthy volunteers, and no immuno-0.5 mL of sterile water for injection and was diluted allergic reactions have been observed as described by with physiological saline to a concentration of 1 mg/mL. Esslinger et al [20] . Since PEG-Hi is eliminated excluThereafter, the solution was administered intravenously sively by renal excretion, impaired renal function might as a single bolus injection of 0.05 mg/kg body weight. have a significant impact on its pharmacokinetics. The
Blood and urine sampling purpose of this study, therefore, was to determine the single-dose pharmacokinetics of intravenous PEG-Hi in Blood samples for the evaluation of anti-IIa activity patients with varying degrees of chronic renal failure (CRF) and clotting parameters were collected in tubes conin comparison to healthy volunteers. taining 1:10 vol/vol 3.8% sodium citrate from HVs and patients before dosing and at 5, 10, 20, and 30 minutes and 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, and 24 hours after METHODS dosing. Additional blood samples were collected from Subjects patients at 36, 48, 60, 72, 84, 96, 108, and 120 hours after dosing. After separation of the citrated blood, the Eight volunteers between the ages of 22 and 60 and samples were immediately centrifuged at 1500 ϫ g for 30 patients between the ages of 26 and 73 with varying 15 minutes at 4ЊC. The resulting plasma was divided into degrees of CRF were enrolled in the study. The subjects aliquots and then shock frozen and stored at Ϫ75ЊC until were assigned to the following groups: group IA, creatianalyzed. Urine was collected from all subjects immedinine clearance (C Cr ) Ն 80 mL/min, healthy volunteers; ately before dosing and during the following intervals: group IB, C Cr Ն 80 mL/min, patients with normal renal 0 to 4, 4 to 8, 8 to 12, and 12 to 24 hours after dosing. function; group II, C Cr 79 to 50 mL/min, patients with Urine collection for patients was extended to 24 to 48, mild CRF; group III, C Cr 49 to 20 mL/min, patients with 48 to 72, 72 to 96, and 96 to 120 hours after dosing. The moderate CRF; and group IV, C Cr Յ 19 mL/min, patients total volume voided during each collection interval was with severe CRF.
recorded, and 10 mL aliquots were shock frozen and The patients' characteristics are shown in Table 1. stored at Ϫ75ЊC until assayed. The final grouping of renal function and the subsequent analyses of the pharmacokinetic data were based on C Cr Anti-IIa activity and pharmacokinetic evaluation values, as determined on the basis of 24-hour urine collection during the in-house study period after PEG-Hi Pharmacokinetic evaluation based on PEG-Hi antiIIa activity was performed using compartment modeldosing. The study was approved by the Ethics Committee of the Faculty of Medicine at the University of Jena independent procedures. Anti-IIa activity in plasma and urine was measured using chromogenic substrate S-2238 up to six-weeks postdose. The "Total IgE" kit (Immunotech, Marseille, France) was used to determine total IgE (Chromogenix, Moelndal, Sweden) according to the method originally described by Spannagl et al [21] . Peak class antibodies. plasma anti-IIa activity (C max ) and time to C max (t max ) were
Statistical analysis recorded as observed. The slowest hybrid rate constant ( z ) and, hence, terminal half-life (t 1/2 ϭ 0.693/ z ) were Statistical analysis was performed with descriptive methods. Dependency of AUC 0-t , t 1/2 , total body clearance calculated from the slope of the terminal portion of log plasma anti-IIa activity versus time course. No descrip-(C TB ) and renal clearance (C Renal ) on creatinine clearance (C Cr ) as well as the relationship between PEG-Hi plasma tive statistics were provided if more than two thirds of the measurements at the respective sampling times were levels and coagulation parameters was analyzed by linear regression. below the limit of quantitation (LOQ ϭ 100 ng/mL).
Coagulation assays and bleeding time RESULTS
Dade reagent (Baxter, Columbia, MD, USA) was used Tolerability to determine the activated partial thromboplastin time (
aPTT). Monitoring of PEG-Hi concentrations consisted
Polyethylene glycol-hirudin was very well tolerated without any serious adverse events. There were no signs of of measuring the ecarin clotting time in the citrated whole blood and plasma using a standardized reagent manufacbleeding in the gastrointestinal tract or urogenital system. The platelet count as well as red and white blood tured by Pentapharm (Basel, Switzerland). The ecarin clotting time is a specific test for the determination of counts (RBC, WBC) were not affected by PEG-Hi. In 18 subjects, IgE class prestudy antibody levels were above hirudin in blood, plasma, or other body fluids. The starting reagent, made of Echis carinatus snake venom, is ecarin.
120 ng/mL, with maximum levels of up to about 1600 ng/mL. However, no allergic reactions were observed Ecarin splits the prothrombin molecule at the arginine 320 peptide bond. This limited proteolysis produces a after injecting PEG-Hi, and IgE levels measured after the study and at six weeks' follow-up were similar to the thrombin intermediate called meizothrombin. Hirudin is able to inhibit meizothrombin with the same extent as baseline values. As a rule, there were no measurable IgG and IgM antibody titers against PEG-Hi. Existing titers thrombin. Meizothrombin also converts fibrinogen into fibrin, but with considerably lower activity than thrombetween 2 2 and 2 4 in eight subjects remained unchanged for up to six weeks after PEG-Hi treatment. Clinical chembin. Fibrin conversion follows reaction kinetics of the first order. Therefore, the calibration curve for hirudin is linear istry [total serum protein, triglycerides, alanine aminotransferase (ALAT), gamma-guanidinium thiocyanate (␥-GT), over a wide concentration range (50 to 5000 ng/mL) [22] . The quantitative estimation of fibrinogen was determined and alkaline phosphatase (APH)] values did not significantly change for up to 120 hours after the administration as the protein concentration by the biuret method. Template bleeding time was measured at a standardized horiof PEG-H. Bilirubin increased within the normal range, whereas aspartate aminotransferase (ASAT) and choleszontal cut on the volar aspect of the forearm made with a Surgicutt device after inflating a sphygmomanometer terol displayed a falling tendency. In all patient groups, serum creatinine values declined after PEG-Hi dosing; cuff on the upper arm to 40 mm Hg [23] .
however, these differences were not statistically signifiSafety assessment cant. Concomitant treatment of underlying diseases was continued and consisted primarily of drugs against hyperRoutine clinical chemistry (including serum creatinine and liver enzyme determinations) was performed, and tension, hyperuricemia, hyperlipidemia, hyperparathyroidism, hypocalcemia, and acidosis. None of the medications hematological parameters were determined during a twoweek prestudy period, shortly before drug administration were considered to interfere with the study objectives. and after the study. The urinary protein pattern was Pharmacodynamics and pharmacokinetic parameters determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) during the prestudy
The mean plasma concentration time profiles and pharmacokinetic parameters for each study group are period. Urine samples were checked repeatedly for hematuria using reagent test strips (Combur 9 -Test) as were shown in Figure 1 and Table 2 , respectively. C max values were similar in all groups. AUC increased distinctly in the feces for occult blood with the hemo-Care test. Echocardiograms, blood pressure, heart rate, and body tempatients with moderate and severe renal failure. Total body clearance from the plasma (C TB ) and renal clearperature were determined before dosing, and after the study. Specific anti-PEG-Hi antibody assays were perance (C Renal ) values as well as recovery of PEG-Hi from the urine decreased, whereas the elimination half-life formed using enzyme immunoassays with peroxidaselabeled goat immunoconjugates against human IgM and (t 1/2 ) increased along with the severity of renal function impairment. Total plasma clearance of PEG-Hi correlated IgG (Nordic, Bochum, Germany), normal limits Ͻ2 6 , for (Figs. 4 and 5) . PEG-Hi admininjection of 0.05 mg/kg PEG-Hi and compared these istration did not prolong bleeding time in either study results with data obtained in healthy volunteers and congroup. Baseline fibrinogen levels in the patients introl patients. PEG-Hi clearance correlates well with C Cr creased parallel to the severity of renal failure, but these (r 2 ϭ 0.86). It accounts for about 20% of C Cr and therevalues were not affected by PEG-Hi treatment (Fig. 6) .
fore reflects well the degree of renal failure. Because of the intravenous administration of PEG-Hi, the peak DISCUSSION plasma concentrations were similar (about 1000 ng/mL) Polyethylene glycol-hirudin proved to be a safe, direct in all study groups. These results are in good agreement thrombin inhibitor in healthy volunteers [20] . Its prowith data previously obtained from healthy volunteers longed duration of action compared with nonconjugated [20] . At four hours postdose, plasma PEG-Hi levels had r-hi is characterized by a fivefold reduction in total plasma already fallen to below 200 ng/mL in healthy volunteers compared with 540 ng/mL in patients with severe renal clearance [20] . Because it is predominantly eliminated ysis sessions. Ecarin clotting time, used to optimize drug failure. The elimination half-life and AUC values corremonitoring of PEG-Hi, was compared with aPTT and lated negatively with PEG-Hi and C Cr . In view of these anti-IIa activity methods. A good correlation between results, PEG-Hi doses have to be adjusted according to ecarin clotting time and nonconjugated r-hi in plasma the extent of CRF. As there is a linear relationship becontaining 50 to 5000 ng/mL was recently reported by tween C Cr and PEG-Hi, the normal starting dose of 0. 08 Nowak et al [18] . In our study, a high correlation between mg/kg body weight PEG-Hi has to be reduced according ecarin clotting time and anti-IIa activity of the PEGto the actual C Cr measured. The therapeutic range of conjugated r-hi was found. This is consistent with the PEG-Hi during hemodialysis is expected to be between results reported by Bode et al [abstract; J Am Coll 600 and 800 ng/mL [19] . This range was found in an early Cardiol 29/2(Suppl A):411, 1997], who found a close clinical study investigating the efficacy of r-hi in chronic dialysis patients undergoing five or ten consecutive diallinear relationship of ecarin clotting time to PEG-Hi
